Using mass spectrometry-based peptidomics to understand the brain and disorders such as Parkinson's disease and schizophrenia

Current Topics in Medicinal Chemistry

Volumn 14, Issue 3, 2014, Pages 369-381

  Café Mendes, Cecília Cerqueira ^a   Ferro, Emer S ^a   Britto, Luiz Roberto G ^a   Martins de Souza, Daniel ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Intracellular peptides; Mass spectrometry; Neuropeptides; Oligopeptidases; Parkinson's disease; Peptidomics; Schizophrenia; Thimet

Indexed keywords

ALPHA NEOENDORPHIN; ALPHA SYNUCLEIN; BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; DYNORPHIN B; GUANIDINOACETATE METHYLTRANSFERASE; HEMOGLOBIN ALPHA CHAIN; HEMOPRESSIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MYELIN ASSOCIATED GLYCOPROTEIN; NEURON SPECIFIC ENOLASE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; PEPTIDE FRAGMENT; PEPTIDE HISTIDINE ISOLEUCINE; PROHIBITIN; PROTEASOME; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VINCULIN; VOLTAGE DEPENDENT ANION CHANNEL;

ALZHEIMER DISEASE; ARTICLE; BRAIN CELL; BRAIN DISEASE; DYSKINESIA; GENE; GENETIC SUSCEPTIBILITY; INTRACELLULAR SIGNALING; MASS SPECTROMETRY; NEUROPSYCHIATRY; PARKINSON DISEASE; PEPTIDOMICS; PROTEIN ANALYSIS; PROTEOMICS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; MASS SPECTROMETRY; PARKINSON DISEASE; PEPTIDES; PROTEOMICS; SCHIZOPHRENIA;

EID: 84894049486     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026613666131204120747     Document Type: Article

References (145)

1. Vajda, F.J. Neuroprotection and neurodegenerative disease. J. Clin. Neurosci., 2002, 9(1), 4-8.
2. Nicotera, P.; Lipton, S.A. Excitotoxins in neuronal apoptosis and necrosis. J. Cereb. Blood Flow Metab., 1999, 19(6), 583-591.
3. Leist, M.; Nicotera, P. Apoptosis, excitotoxicity, and neuropathology. Exp. Cell Res., 1998, 239(2), 183-201.
4. Nimmerjahn, A.; Kirchhoff, F.; Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 2005, 308(5726), 1314-1318.
5. Wang, W.; Bu, B.; Xie, M.; Zhang, M.; Yu, Z.; Tao, D. Neural cell cycle dysregulation and central nervous system diseases. Prog. Neurobiol., 2009, 89(1), 1-17.
6. Beal, M.F. Mitochondria, free radicals, and neurodegeneration. Curr. Opin. Neurobiol., 1996, 6(5), 661-666.
7. Nicholls, D.G.; Budd, S.L. Neuronal excitotoxicity: the role of mitochondria. Biofactors, 1998, 8(3-4), 287-299.
8. Gubellini, P.; Picconi, B.; Di Filippo, M.; Calabresi, P. Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neurodegenerative diseases. Biochim. Biophys. Acta, 2010, 1802(1), 151-161.
9. Licker, V.; Kovari, E.; Hochstrasser, D.F.; Burkhard, P.R. Proteomics in human Parkinson's disease research. J.Proteomics., 2009, 73(1), 10-29.
10. Ferrer, I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog. Neurobiol., 2009, 88(2), 89-103.
11. Jellinger, K.A. Potential role of alpha-synuclein in neurodegeneration: studies in a rat animal model. J. Neurochem., 2012, 122(4), 659-660.
12. Moore, D.J.; West, A.B.; Dawson, V.L.; Dawson, T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 2005, 28(57-87).
13. Taurines, R.; Dudley, E.; Grassl, J.; Warnke, A.; Gerlach, M.; Coogan, A.N.; Thome, J. Proteomic research in psychiatry. J. Psychopharmacol., 2011, 25(2), 151-196.
14. Rosenzweig-Lipson, S.; Beyer, C.E.; Hughes, Z.A.; Khawaja, X.; Rajarao, S.J.; Malberg, J.E.; Rahman, Z.; Ring, R.H.; Schechter, L.E. Differentiating antidepressants of the future: efficacy and safety. Pharmacol. Ther., 2007, 113(1), 134-153.
15. Torrey, E.F. Surviving schizophrenia: a manual for families, patients, and providers, 5th ed.; Collins: New York, 2006.
16. Baumeister, A.A.; Francis, J.L. Historical development of the dopamine hypothesis of schizophrenia. J. Hist. Neurosci., 2002, 11(3), 265-277.
17. Kapur, S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry, 2003, 160(1), 13-23.
18. Faludi, G.; Dome, P.; Lazary, J. Origins and perspectives of schizophrenia research. Neuropsychopharmacol. Hung., 2011, 13(4), 185-192.
19. Lauzon, N.M.; Laviolette, S.R. Dopamine D4-receptor modulation of cortical neuronal network activity and emotional processing: Implications for neuropsychiatric disorders. Behav. Brain Res., 2010, 208(1), 12-22.
20. Martins-de-Souza, D.; Turck, C.W. Proteomic biomarkers for psychiatric disorders: a progress update. Biomark. Med., 2012, 6(2), 189-192.
21. Jablensky, A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur.Arch Psychiatry Clin. Neurosci., 2000, 250(6), 274-285.
22. Wong, A.H.; Van Tol, H.H. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev., 2003, 27(3), 269-306.
23. Walker, E.F. Developmentally moderated expressions of the neuropathology underlying schizophrenia. Schizophr. Bull., 1994, 20(3), 453-480.
24. Jones, P.; Rodgers, B.; Murray, R.; Marmot, M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet, 1994, 344(8934), 1398-1402.
25. Horga, G.; Bernacer, J.; Dusi, N.; Entis, J.; Chu, K.; Hazlett, E.A.; Haznedar, M.M.; Kemether, E.; Byne, W.; Buchsbaum, M.S. Correlations between ventricular enlargement and gray and white matter volumes of cortex, thalamus, striatum, and internal capsule in schizophrenia. Eur Arch Psychiatry Clin. Neurosci., 2011, 261(7), 467-476.
26. Tost, H.; Alam, T.; Meyer-Lindenberg, A. Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev, 2010, 34(5), 689-700.
27. Gur, R.E.; Maany, V.; Mozley, P.D.; Swanson, C.; Bilker, W.; Gur, R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry, 1998, 155(12), 1711-1717.
28. Meyer-Lindenberg, A. Neuroimaging and the question of neurodegeneration in schizophrenia. Prog Neurobiol, 2011, 95(4), 514-516.
29. Martins-De-Souza, D.; Dias-Neto, E.; Schmitt, A.; Falkai, P.; Gormanns, P.; Maccarrone, G.; Turck, C.W.; Gattaz, W.F. Proteome analysis of schizophrenia brain tissue. World J. Biol. Psychiatry, 2010, 11(2), 110-120.
30. Bassett, D.S.; Bullmore, E.T.; Meyer-Lindenberg, A.; Apud, J.A.; Weinberger, D.R.; Coppola, R. Cognitive fitness of cost-efficient brain functional networks. Proc Natl Acad Sci U S A, 2009, 106(28), 11747-11752.
31. Berman, K.F.; Weinberger, D.R. The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: in vivo physiological correlates of cognitive deficits. Prog. Brain Res., 1990, 85(521-536); discussion 536-527.
32. Liddle, E.B.; Bates, A.T.; Das, D.; White, T.P.; Groom, M.J.; Jansen, M.; Jackson, G.M.; Hollis, C.; Liddle, P.F. Inefficient cerebral recruitment as a vulnerability marker for schizophrenia. Psychol. Med., 2013, 43(1), 169-182.
33. Kong, L.; Herold, C.; Stieltjes, B.; Essig, M.; Seidl, U.; Wolf, R.C.; Wustenberg, T.; Lasser, M.M.; Schmid, L.A.; Schnell, K.; Hirjak, D.; Thomann, P.A. Reduced gray to white matter tissue intensity contrast in schizophrenia. PLoS One, 2012, 7(5), e37016.
34. Felsky, D.; Voineskos, A.N.; Lerch, J.P.; Nazeri, A.; Shaikh, S.A.; Rajji, T.K.; Mulsant, B.H.; Kennedy, J.L. Myelin-associated glycoprotein gene and brain morphometry in schizophrenia. Front Psychiatry, 2012, 3(40).
35. Freeman, W.M.; Hemby, S.E. Proteomics for protein expression profiling in neuroscience. Neurochem. Res., 2004, 29(6), 1065-1081.
36. Martins-de-Souza, D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J. Psychiatr. Res., 2010, 44(3), 149-156.
37. Schwarz, S.; Froelich, L.; Burns, A. Pharmacological treatment of dementia. Curr. Opin. Psychiatry, 2012, 25(6), 542-550.
38. Singh, I.; Rose, N. Biomarkers in psychiatry. Nature, 2009, 460(7252), 202-207.
39. Martins-de-Souza, D.; Guest, P.C.; Vanattou-Saifoudine, N.; Harris, L.W.; Bahn, S. Proteomic technologies for biomarker studies in psychiatry: advances and needs. Int. Rev. Neurobiol., 2011, 101(65-94).
40. Lakhan, S.E.; Vieira, K.; Hamlat, E. Biomarkers in psychiatry: drawbacks and potential for misuse. Int. Arch. Med., 2010, 3(1)
41. Martins-de-Souza, D.; Gattaz, W.F.; Schmitt, A.; Rewerts, C.; Marangoni, S.; Novello, J.C.; Maccarrone, G.; Turck, C.W.; Dias-Neto, E. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J. Neural. Transm., 2009, 116(3), 275-289.
42. Zhang, X.; Yin, X.; Yu, H.; Liu, X.; Yang, F.; Yao, J.; Jin, H.; Yang, P. Quantitative proteomic analysis of serum proteins in patients with Parkinson's disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. Analyst, 2012, 137(2), 490-495.
43. Alberio, T.; Bossi, A.M.; Milli, A.; Parma, E.; Gariboldi, M.B.; Tosi, G.; Lopiano, L.; Fasano, M. Proteomic analysis of dopamine and alpha-synuclein interplay in a cellular model of Parkinson's disease pathogenesis. FEBS J, 2010, 277(23), 4909-4919.
44. Xun, Z.; Sowell, R.A.; Kaufman, T.C.; Clemmer, D.E. Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease. Mol. Cell. Proteomics, 2008, 7(7), 1191-1203.
45. Park, B.; Yang, J.; Yun, N.; Choe, K.M.; Jin, B.K.; Oh, Y.J. Proteomic analysis of expression and protein interactions in a 6- hydroxydopamine-induced rat brain lesion model. Neurochem. Int., 2010, 57(1), 16-32.
46. Sousa, V.L.; Bellani, S.; Giannandrea, M.; Yousuf, M.; Valtorta, F.; Meldolesi, J.; Chieregatti, E. {alpha}-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol. Biol. Cell., 2009, 20(16), 3725-3739.
47. Esposito, A.; Dohm, C.P.; Kermer, P.; Bahr, M.; Wouters, F.S. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol. Dis., 2007, 26(3), 521-531.
48. Valastro, B.; Dekundy, A.; Krogh, M.; Lundblad, M.; James, P.; Danysz, W.; Quack, G.; Cenci, M.A. Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J. Neurochem, 2007, 102(4), 1395-1409.
49. Hakak, Y.; Walker, J.R.; Li, C.; Wong, W.H.; Davis, K.L.; Buxbaum, J.D.; Haroutunian, V.; Fienberg, A.A. Genome-wide expression analysis reveals dysregulation of myelination-related Using Mass Spectrometry-Based Peptidomics to Understand the Brain genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U S A, 2001, 98(8), 4746-4751.
50. Tkachev, D.; Mimmack, M.L.; Ryan, M.M.; Wayland, M.; Freeman, T.; Jones, P.B.; Starkey, M.; Webster, M.J.; Yolken, R.H.; Bahn, S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet, 2003, 362(9386), 798-805.
51. Aston, C.; Jiang, L.; Sokolov, B.P. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res., 2004, 77(6), 858-866.
52. Harrison, P.J.; Weinberger, D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry, 2005, 10(1), 40-68; image 45.
53. Varadarajulu, J.; Schmitt, A.; Falkai, P.; Alsaif, M.; Turck, C.W.; Martins-de-Souza, D. Differential expression of HINT1 in schizophrenia brain tissue. Eur. Arch Psychiatry. Clin. Neurosci., 2012, 262(2), 167-172.
54. Bernstein, H.G.; Krell, D.; Braunewell, K.H.; Baumann, B.; Gundelfinger, E.D.; Diekmann, S.; Danos, P.; Bogerts, B. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J Neurocytol, 2001, 30(8), 661-670.
55. Martins-de-Souza, D.; Gattaz, W.F.; Schmitt, A.; Maccarrone, G.; Hunyadi-Gulyas, E.; Eberlin, M.N.; Souza, G.H.; Marangoni, S.; Novello, J.C.; Turck, C.W.; Dias-Neto, E. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res, 2009, 43(11), 978-986.
56. Middleton, F.A.; Peng, L.; Lewis, D.A.; Levitt, P.; Mirnics, K. Altered expression of 14-3-3 genes in the prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology, 2005, 30(5), 974-983.
57. Altar, C.A.; Vawter, M.P., and Ginsberg, S.D. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology, 2009, 34(1), 18-54.
58. Martins-de-Souza, D. Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin. Neurosci., 2010, 260(7), 561-562.
59. Sweitzer, S.M.; Hinshaw, J.E. Dynamin undergoes a GTP- dependent conformational change causing vesiculation. Cell, 1998, 93(6), 1021-1029.
60. Dale, L.B.; Babwah, A.V.; Ferguson, S.S. Mechanisms of metabotropic glutamate receptor desensitization: role in the patterning of effector enzyme activation. Neurochem. Int., 2002, 41(5), 319-326.
61. Webster, M.J.; O'Grady, J.; Kleinman, J.E.; Weickert, C.S. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience, 2005, 133(2), 453-461.
62. Bernstein, H.G.; Steiner, J.; Bogerts, B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother, 2009, 9(7), 1059-1071.
63. Huang, J.T.; Leweke, F.M.; Oxley, D.; Wang, L.; Harris, N.; Koethe, D.; Gerth, C.W.; Nolden, B.M.; Gross, S.; Schreiber, D.; Reed, B.; Bahn, S. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med, 2006, 3(11), e428.
64. Ljungdahl, A.; Hanrieder, J.; Falth, M.; Bergquist, J., and Andersson, M. Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease. PLoS One, 2011, 6(9), e25653.
65. N.G. What lies ahead for the proprotein convertases? Ann. N Y. Acad. Sci., 2011, 1220(149-161).
66. Mzhavia, N.; Qian, Y.; Feng, Y.; Che, F.Y.; Devi, L.A.; Fricker, L.D. Processing of proSAAS in neuroendocrine cell lines. Biochem. J., 2002, 361(Pt 1), 67-76.
67. Zhang, X.; Pan, H.; Peng, B.; Steiner, D.F.; Pintar, J.E.; Fricker, L.D. Neuropeptidomic analysis establishes a major role for prohormone convertase-2 in neuropeptide biosynthesis. J. Neurochem., 2010, 112(5), 1168-1179.
68. Dong, W.; Fricker, L.D.; Day, R. Carboxypeptidase D is a potential candidate to carry out redundant processing functions of carboxypeptidase E based on comparative distribution studies in the rat central nervous system. Neuroscience, 1999, 89(4), 1301-1317.
69. Guthals, A.; Bandeira, N. Peptide identification by tandem mass spectrometry with alternate fragmentation modes. Mol. Cell. Proteomics., 2012, 11(9), 550-557.
70. Thibault, D.; Albert, P.R.; Pineyro, G.; Trudeau, L.E. Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism. J. Biol. Chem., 2011, 286(11), 9174-9184.
71. Ferraro, L.; Beggiato, S.; Tomasini, M.C.; Fuxe, K.; Tanganelli, S.; Antonelli, T. Neurotensin regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor functional activity: an in vivo microdialysis study. J. Neurosci. Res., 2011, 89(10), 1618-1626.
72. Hamid, E.H.; Hyde, T.M.; Egan, M.F.; Wolf, S.S.; Herman, M.M.; Nemeroff, C.B.; Kleinman, J.E. Neurotensin receptor binding abnormalities in the entorhinal cortex in schizophrenia and affective disorders. Biol. Psychiatry., 2002, 51(10), 795-800.
73. Boules, M.; Warrington, L.; Fauq, A.; McCormick, D.; Richelson, E. Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. Eur. J. Pharmacol., 2001, 428(2), 227-233.
74. Schimpff, R.M.; Avard, C.; Fenelon, G.; Lhiaubet, A.M.; Tenneze, L.; Vidailhet, M.; Rostene, W. Increased plasma neurotensin concentrations in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2001, 70(6), 784-786.
75. Stolakis, V.; Kalafatakis, K.; Botis, J.; Zarros, A.; Liapi, C. The regulatory role of neurotensin on the hypothalamic-anterior pituitary axons: emphasis on the control of thyroid-related functions. Neuropeptides, 2010, 44(1), 1-7.
76. Stanic, D.; Mulder, J.; Watanabe, M.; Hokfelt, T. Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules.J Comp. Neurol., 2011, 519(7), 1219-1257.
77. Morales-Medina, J.C.; Dumont, Y.; Quirion, R. A possible role of neuropeptide Y in depression and stress. Brain Res, 2010, 1314(194-205.
78. Geerling, J.J.; Wang, Y.; Havekes, L.M.; Romijn, J.A.; Rensen, P.C. Acute central neuropeptide y administration increases food intake but does not affect hepatic very low-density lipoprotein (vldl) production in mice. PLoS One, 2013, 8(2), e55217.
79. Stafford, J.M.; Yu, F.; Printz, R.; Hasty, A.H.; Swift, L.L.; Niswender, K.D. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes, 2008, 57(6), 1482-1490.
80. Horvath, G.; Racz, B.; Reglodi, D.; Kovacs, K.; Kiss, P.; Gallyas, F., Jr.; Bognar, Z.; Szabo, A.; Magyarlaki, T.; Laszlo, E.; Lubics, A.; Tamas, A.; Toth, G.; Szakaly, P. Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusion. J. Mol. Neurosci., 2010, 42(3), 411-418.
81. Dejda, A.; Sokolowska, P.; Nowak, J.Z. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol. Rep., 2005, 57(3), 307-320.
82. Zhang, X.; Che, F.Y.; Berezniuk, I.; Sonmez, K.; Toll, L.; Fricker, L.D. Peptidomics of Cpe(fat/fat) mouse brain regions: implications for neuropeptide processing. J. Neurochem., 2008, 107(6), 1596-1613.
83. Baggerman, G.; Verleyen, P.; Clynen, E.; Huybrechts, J.; De Loof, A.; Schoofs, L. Peptidomics. J.Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004, 803(1), 3-16.
84. Gelman, J.S.; Wardman, J.; Bhat, V.B.; Gozzo, F.C.; Fricker, L.D. Quantitative peptidomics to measure neuropeptide levels in animal models relevant to psychiatric disorders. Methods Mol. Biol., 2012, 829(487-503.
85. Richter, R.; Schulz-Knappe, P.; Schrader, M.; Standker, L.; Jurgens, M.; Tammen, H.; Forssmann, W.G. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J. Chromatogr. B Biomed. Sci. Appl., 1999, 726(1-2), 25-35.
86. Pierotti, A.; Dong, K.W.; Glucksman, M.J.; Orlowski, M.; Roberts, J.L. Molecular cloning and primary structure of rat testes metalloendopeptidase EC 3.4.24.15. Biochemistry, 1990, 29(45), 10323-10329.
87. Fontenele-Neto, J.D.; Massarelli, E.E.; Gurgel Garrido, P.A.; Beaudet, A.; Ferro, E.S. Comparative fine structural distribution of endopeptidase 24.15 (EC3.4.24.15) and 24.16 (EC3.4.24.16) in rat brain. J. Comp. Neurol., 2001, 438(4), 399-410.
88. Silva, C.L.; Portaro, F.C.; Bonato, V.L.; de Camargo, A.C.; Ferro, E.S. Thimet oligopeptidase (EC 3.4.24.15), a novel protein on the route of MHC class I antigen presentation. Biochem. Biophys. Res. Commun., 1999, 255(3), 591-595.
89. Cunha, F.M.; Berti, D.A.; Ferreira, Z.S.; Klitzke, C.F.; Markus, R.P.; Ferro, E.S. Intracellular peptides as natural regulators of cell signaling. J. Biol. Chem., 2008, 283(36), 24448-24459.
90. Rioli, V.; Gozzo, F.C.; Heimann, A.S.; Linardi, A.; Krieger, J.E.; Shida, C.S.; Almeida, P.C.; Hyslop, S.; Eberlin, M.N.; Ferro, E.S. Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme. J Biol Chem, 2003, 278(10), 8547-8555.
91. Dale, C.S.; Pagano Rde, L.; Rioli, V.; Hyslop, S.; Giorgi, R.; Ferro, E.S. Antinociceptive action of hemopressin in experimental hyperalgesia. Peptides, 2005, 26(3), 431-436.
92. Gupta, A.; Decaillot, F.M.; Gomes, I.; Tkalych, O.; Heimann, A.S.; Ferro, E.S.; Devi, L.A. Conformation state-sensitive antibodies to G-protein-coupled receptors. J. Biol. Chem., 2007, 282(8), 5116-5124.
93. Heimann, A.S.; Gomes, I.; Dale, C.S.; Pagano, R.L.; Gupta, A.; de Souza, L.L.; Luchessi, A.D.; Castro, L.M.; Giorgi, R.; Rioli, V.; Ferro, E.S.; Devi, L.A. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc. Natl. Acad. Sci. U S A, 2007, 104(51), 20588-20593.
94. Gomes, I.; Grushko, J.S.; Golebiewska, U.; Hoogendoorn, S.; Gupta, A.; Heimann, A.S.; Ferro, E.S.; Scarlata, S.; Fricker, L.D.; Devi, L.A. Novel endogenous peptide agonists of cannabinoid receptors. FASEB J., 2009, 23(9), 3020-3029.
95. Bauer, M.; Chicca, A.; Tamborrini, M.; Eisen, D.; Lerner, R.; Lutz, B.; Poetz, O.; Pluschke, G.; Gertsch, J. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J. Biol. Chem., 2012, 287(44), 36944-36967.
96. Fricker, L.D. Analysis of mouse brain peptides using mass spectrometry-based peptidomics: implications for novel functions ranging from non-classical neuropeptides to microproteins. Mol. Biosyst., 2010, 6(8), 1355-1365.
97. Gelman, J.S.; Dasgupta, S.; Berezniuk, I.; Fricker, L.D. Analysis of peptides secreted from cultured mouse brain tissue. Biochim. Biophys. Acta, 2013,
98. Benito, C.; Nunez, E.; Tolon, R.M.; Carrier, E.J.; Rabano, A.; Hillard, C.J.; Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque- associated glia in Alzheimer's disease brains. J. Neurosci., 2003, 23(35), 11136-11141.
99. Castro, L.M.; Berti, D.A.; Russo, L.C.; Coelho, V.; Gozzo, F.C.; Oliveira, V.; Ferro, E.S. Similar intracellular peptide profile of TAP1/beta2 microglobulin double-knockout mice and C57BL/6 wild-type mice as revealed by peptidomic analysis. AAPS J, 2010, 12(4), 608-616.
100. Gelman, J.S.; Sironi, J.; Castro, L.M.; Ferro, E.S.; Fricker, L.D. Peptidomic analysis of human cell lines. J. Proteome. Res., 2011, 10(4), 1583-1592.
101. Goldberg, A.L. Protein degradation and protection against misfolded or damaged proteins. Nature, 2003, 426(6968), 895-899.
102. Saric, T.; Graef, C.I.; Goldberg, A.L. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J. Biol. Chem., 2004, 279(45), 46723-46732.
103. Fricker, L.D.; Gelman, J.S.; Castro, L.M.; Gozzo, F.C.; Ferro, E.S. Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides. J. Proteome. Res., 2012, 11(3), 1981-1990.
104. Ferro, E.S.; Hyslop, S.; Camargo, A.C. Intracellullar peptides as putative natural regulators of protein interactions. J. Neurochem., 2004, 91(4), 769-777.
105. Russo, L.C.; Asega, A.F.; Castro, L.M.; Negraes, P.D.; Cruz, L.; Gozzo, F.C.; Ulrich, H.; Camargo, A.C.; Rioli, V.; Ferro, E.S. Natural intracellular peptides can modulate the interactions of mouse brain proteins and thimet oligopeptidase with 14-3-3epsilon and calmodulin. Proteomics, 2012, 12(17), 2641-2655.
106. Berezniuk, I.; Sironi, J.; Callaway, M.B.; Castro, L.M.; Hirata, I.Y.; Ferro, E.S.; Fricker, L.D. CCP1/Nna1 functions in protein turnover Café-Mendes et al. in mouse brain: Implications for cell death in Purkinje cell degeneration mice. FASEB J., 2010, 24(6), 1813-1823.
107. Heimann, A.S.; Favarato, M.H.; Gozzo, F.C.; Rioli, V.; Carreno, F.R.; Eberlin, M.N.; Ferro, E.S.; Krege, J.H.; Krieger, J.E. ACE gene titration in mice uncovers a new mechanism for ACE on the control of body weight. Physiol. Genomics, 2005, 20(2), 173-182.
108. Kondo, T.; Plaza, S.; Zanet, J.; Benrabah, E.; Valenti, P.; Hashimoto, Y.; Kobayashi, S.; Payre, F.; Kageyama, Y. Small peptides switch the transcriptional activity of Shavenbaby during Drosophila embryogenesis. Science, 2010, 329(5989), 336-339.
109. Hanyu-Nakamura, K.; Sonobe-Nojima, H.; Tanigawa, A.; Lasko, P.; Nakamura, A. Drosophila Pgc protein inhibits P-TEFb recruitment to chromatin in primordial germ cells. Nature, 2008, 451(7179), 730-733.
110. Hashimoto, Y.; Kondo, T.; Kageyama, Y. Lilliputians get into the limelight: novel class of small peptide genes in morphogenesis. Dev Growth Differ, 2008, 50 Suppl 1(S269-276.
111. Reits, E.; Griekspoor, A.; Neijssen, J.; Groothuis, T.; Jalink, K.; van Veelen, P.; Janssen, H.; Calafat, J.; Drijfhout, J.W.; Neefjes, J. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity, 2003, 18(1), 97-108.
112. Slemmon, J.R.; Hughes, C.M.; Campbell, G.A.; Flood, D.G. Increased levels of hemoglobin-derived and other peptides in Alzheimer's disease cerebellum. J. Neurosci., 1994, 14(4), 2225-2235.
113. Poljak, A.; McLean, C.A.; Sachdev, P.; Brodaty, H.; Smythe, G.A. Quantification of hemorphins in Alzheimer's disease brains. J. Neurosci. Res., 2004, 75(5), 704-714.
114. Che, F.Y.; Yuan, Q.; Kalinina, E.; Fricker, L.D. Peptidomics of Cpe fat/fat mouse hypothalamus: effect of food deprivation and exercise on peptide levels. J. Biol. Chem., 2005, 280(6), 4451-4461.
115. Skold, K.; Svensson, M.; Kaplan, A.; Bjorkesten, L.; Astrom, J.; Andren, P.E. A neuroproteomic approach to targeting neuropeptides in the brain. Proteomics, 2002, 2(4), 447-454.
116. Brantl, V.; Gramsch, C.; Lottspeich, F.; Mertz, R.; Jaeger, K.H.; Herz, A. Novel opioid peptides derived from hemoglobin: hemorphins. Eur. J. Pharmacol., 1986, 125(2), 309-310.
117. Blishchenko, E.Y.; Sazonova, O.V.; Kalinina, O.A.; Yatskin, O.N.; Philippova, M.M.; Surovoy, A.Y.; Karelin, A.A.; Ivanov, V.T. Family of hemorphins: co-relations between amino acid sequences and effects in cell cultures. Peptides, 2002, 23(5), 903-910.
118. Pollio, G.; Hoozemans, J.J.; Andersen, C.A.; Roncarati, R.; Rosi, M.C.; van Haastert, E.S.; Seredenina, T.; Diamanti, D.; Gotta, S.; Fiorentini, A.; Magnoni, L.; Raggiaschi, R.; Rozemuller, A.J.; Casamenti, F.; Caricasole, A.; Terstappen, G.C. Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicity. Neurobiol. Dis., 2008, 31(1), 145-158.
119. Conn, K.J.; Pietropaolo, M.; Ju, S.T.; Abraham, C.R. Monoclonal antibodies against the human metalloprotease EC 3.4.24.15 label neurofibrillary tangles in Alzheimer's disease brain. J. Neurochem., 1996, 66(5), 2011-2018.
120. Pickart, C.M.; Eddins, M.J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta, 2004, 1695(1-3), 55-72.
121. Thompson, S.J.; Loftus, L.T.; Ashley, M.D.; Meller, R. Ubiquitin-proteasome system as a modulator of cell fate. Curr.Opin. Pharmacol., 2008, 8(1), 90-95.
122. Tan, E.K.; Skipper, L.M. Pathogenic mutations in Parkinson disease. Hum. Mutat., 2007, 28(7), 641-653.
123. Rajan, R.S.; Illing, M.E.; Bence, N.F.; Kopito, R.R. Specificity in intracellular protein aggregation and inclusion body formation. Proc. Natl. Acad. Sci. U S A, 2001, 98(23), 13060-13065.
124. Guest, P.C.; Wang, L.; Harris, L.W.; Burling, K.; Levin, Y.; Ernst, A.; Wayland, M.T.; Umrania, Y.; Herberth, M.; Koethe, D.; van Beveren, J.M.; Rothermundt, M.; McAllister, G.; Leweke, F.M.; Steiner, J.; Bahn, S. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol. Psychiatry, 2010, 15(2), 118-119.
125. Pillai, A.; Mahadik, S.P. Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. Schizophr. Res., 2006, 87(1-3), 48-59.
126. Fulzele, S.; Pillai, A. Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. Schizophr. Res., 2009, 115(2-3), 372-373. Using Mass Spectrometry-Based Peptidomics to Understand the Brain
127. McOmish, C.E.; Burrows, E.; Howard, M.; Scarr, E.; Kim, D.; Shin, H.S.; Dean, B.; van den Buuse, M.; Hannan, A.J. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol. Psychiatry, 2008, 13(7), 661-672.
128. Law, A.J.; Wang, Y.; Sei, Y.; O'Donnell, P.; Piantadosi, P.; Papaleo, F.; Straub, R.E.; Huang, W.; Thomas, C.J.; Vakkalanka, R.; Besterman, A.D.; Lipska, B.K.; Hyde, T.M.; Harrison, P.J.; Kleinman, J.E.; Weinberger, D.R. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase- p110delta inhibition as a potential therapeutic strategy. Proc. Natl.Acad. Sci. U S A, 2012, 109(30), 12165-12170.
129. Stefansson, H.; Sigurdsson, E.; Steinthorsdottir, V.; Bjornsdottir, S.; Sigmundsson, T.; Ghosh, S.; Brynjolfsson, J.; Gunnarsdottir, S.; Ivarsson, O.; Chou, T.T.; Hjaltason, O.; Birgisdottir, B.; Jonsson, H.; Gudnadottir, V.G.; Gudmundsdottir, E.; Bjornsson, A.; Ingvarsson, B.; Ingason, A.; Sigfusson, S.; Hardardottir, H.; Harvey, R.P.; Lai, D.; Zhou, M.; Brunner, D.; Mutel, V.; Gonzalo, A.; Lemke, G.; Sainz, J.; Johannesson, G.; Andresson, T.; Gudbjartsson, D.; Manolescu, A.; Frigge, M.L.; Gurney, M.E.; Kong, A.; Gulcher, J.R.; Petursson, H.; Stefansson, K. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet., 2002, 71(4), 877-892.
130. Mann, M.; Hendrickson, R.C.; Pandey, A. Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem., 2001, 70(437-473.
131. Gygi, S.P.; Rist, B.; Gerber, S.A.; Turecek, F.; Gelb, M.H.; Aebersold, R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol., 1999, 17(10), 994-999.
132. Ross, P.L.; Huang, Y.N.; Marchese, J.N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; Purkayastha, S.; Juhasz, P.; Martin, S.; Bartlet-Jones, M.; He, F.; Jacobson, A.; Pappin, D.J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics, 2004, 3(12), 1154-1169.
133. Schmidt, A.; Kellermann, J.; Lottspeich, F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics, 2005, 5(1), 4-15.
134. Ong, S.E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D.B.; Steen, H.; Pandey, A.; Mann, M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteomics, 2002, 1(5), 376-386.
135. Wu, C.C.; MacCoss, M.J.; Howell, K.E.; Matthews, D.E.; Yates, J.R., 3rd Metabolic labeling of mammalian organisms with stable isotopes for quantitative proteomic analysis. Anal. Chem., 2004, 76(17), 4951-4959.
136. Patwardhan, A.J.; Strittmatter, E.F.; Camp, D.G., 2nd; Smith, R.D.; Pallavicini, M.G. Quantitative proteome analysis of breast cancer cell lines using 18O-labeling and an accurate mass and time tag strategy. Proteomics, 2006, 6(9), 2903-2915.
137. Soloviev, M.; Finch, P. Peptidomics, current status. J.Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 815(1-2), 11-24.
138. Kang, U.B.; Yeom, J.; Kim, H.; Lee, C. Quantitative analysis of mTRAQ-labeled proteome using full MS scans. J. Proteome. Res., 2010, 9(7), 3750-3758.
139. Gerber, S.A.; Rush, J.; Stemman, O.; Kirschner, M.W.; Gygi, S.P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U S A, 2003, 100(12), 6940-6945.
140. Kirkpatrick, D.S.; Gerber, S.A.; Gygi, S.P. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods, 2005, 35(3), 265-273.
141. Li, G.Z.; Vissers, J.P.; Silva, J.C.; Golick, D.; Gorenstein, M.V.; Geromanos, S.J. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics, 2009, 9(6), 1696-1719.
142. Emmett, M.R.; Andren, P.E.; Caprioli, R.M. Specific molecular mass detection of endogenously released neuropeptides using in vivo microdialysis/mass spectrometry. J. Neurosci. Methods, 1995, 62(1-2), 141-147.
143. Davies, M.I.; Cooper, J.D.; Desmond, S.S.; Lunte, C.E.; Lunte, S.M. Analytical considerations for microdialysis sampling. Adv. Drug Deliv. Rev., 2000, 45(2-3), 169-188.
144. Berti, D.A.; Russo, L.C.; Castro, L.M.; Cruz, L.; Gozzo, F.C.; Heimann, J.C.; Lima, F.B.; Oliveira, A.C.; Andreotti, S.; Prada, P.O.; Heimann, A.S.; Ferro, E.S. Identification of intracellular peptides in rat adipose tissue: Insights into insulin resistance. Proteomics, 2012, 12(17), 2668-2681.
145. Perkins, D.N.; Pappin, D.J.; Creasy, D.M., Cottrell, J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis, 1999, 20(18), 3551-3567.